Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›AMGN›Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

Ensayo de AMGEN INC en Chemotherapy-induced Febrile Neutropenia (del registro, en inglés).

Fase
no aplica
Estado
Completado
Participantes
1.007
previstos
Centros
90
Fin del objetivo primario
dic 2013
fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en dic 2012.

De principio a fin

  1. Empieza el ensayo (dic 2012)
  2. Lectura de resultados dic 2013 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia (Baseline (prior to participant enrolment)) (del registro, en inglés)

Qué se prueba

Estudio observacional prospectivo sobre cómo los médicos valoran el riesgo de neutropenia febril en pacientes que recibirán quimioterapia.

Lo que dice el documentoThis is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy. Approximately 150-200 investigators will take part in about 100 sites in Europe, Canada and Australia. Approximately 1000 subjects will be studied, all of whom will have non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), non-Hodgkin's lymphoma (NHL) or breast cancer and will be due to receive one of the specific chemotherapy regimens of interest. Investigators' approach to FN risk assessment will be studied using lists of possible risk factors they may consider during their assessment. Investigators will be asked to select and rank the factors they consider the most important when assessing the overall FN risk of a subject and when making the decision whether to treat with granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (PP). They will be asked to make these selections based initially on their own routine clinical practise and subsequently relating specifically to each subject recruited. This is a non-interventional study that involves no procedures outside normal care for the subjects; all data collection will be completed prior to chemotherapy administration.

Más ensayos de AMGN

EnsayoFaseEstadoLectura de resultados
InebilizumabFase 3En marcha, sin reclutarabr 2024 (real)
inebilizumab · MINTFase 3En marcha, sin reclutarmay 2024 (real)
Tarlatamab · DeLLphi-304Fase 3En marcha, sin reclutarene 2025 (real)
Tarlatamab · DeLLphi-307Fase 2En marcha, sin reclutarmar 2025 (real)
Maridebart CafraglutideFase 2En marcha, sin reclutaroct 2025 (real)
Erenumab Dose 1 · OASIS(EM)Fase 3En marcha, sin reclutarnov 2025 (real)

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01813721), actualizada en feb 2017.